Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Gain Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 1.71 · gapped above the open, then crossed back over prior close. High/low 1.72 at 9:30 am ET, 1.70 at 11:00 am ET.
GANX (Gain Therapeutics, Inc.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
49 institutional managers report a position in Gain Therapeutics, Inc. worth $17.8M between them, filed on form 13F for the quarter ending 2026-06-30. 12 of them hold 80% of it, the largest being Marshall Wace LLP at 21.88%.
24 more managers in the register
12 managers hold 80% of the $17.8M institutional base. The other 37 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via Marshall Wace LLP, Potomac Capital Management, Inc. · 21.88% of GANX, 41.27% of SVC
via Marshall Wace LLP, Cambridge Investment Research Advisors, Inc. · 21.88% of GANX, 24.42% of NVA
via Marshall Wace LLP, GSA Capital Partners LLP, Bridgeway Capital Management Inc · 21.88% of GANX, 17.44% of STEM
via Marshall Wace LLP · 21.88% of GANX, 28.83% of ANNA
via Marshall Wace LLP · 21.88% of GANX, 22.90% of EDRY
via Marshall Wace LLP · 21.88% of GANX, 21.94% of ALAR
Managers holding a meaningful stake in GANX also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.